Collegium Pharmaceutical (COLL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.92
- Estimate
- $1.77
- Surprise
- +8.8%
- Revenue (period 2026-06-30)
- $199.9M
- Score at report (before → after)
- 6.5 → 6.6/10
Revenue source: xbrl.
How the report landed
Collegium Pharmaceutical (COLL) beat the $1.77 estimate with diluted EPS of $1.92 — a clear 8.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Sell at 6.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates COLL Sell at 5.9/10.
3 of the last 4 quarters beat the estimate; this quarter's +8.8% surprise compares with a +10.2% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Supplier: API sole or limited-source suppliers
- Concentration risk — Supplier: Patheon (contract manufacturer for Xtampza ER and Nucynta ER)
- Leverage penalty (D/E 3.9): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $22.80
- Price target
- $42.51
- Stop
- $21.96
- Upside to target
- +86.4%
- Reward-to-risk
- 9.8:1
The stock trades at 17.9× trailing but 3.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 12 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
COLL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $705.2M
- P/E (fwd)
- 3.4
- P/E (ttm)
- 17.9
- 52-week range
- $22.64–$50.79
- Off 52-week high
- 55.1%
- RSI (14)
- 12
- Volume vs avg
- 0.79×
- Score today
- 5.9/10